2 results
Approved WMOCompleted
Primary objective:The primary objective is the difference between the gammaCore®-R and the sham treatment groups in mean reduction in number of episodic migraine days during the last four weeks in the twelve-week randomized period compared with the…
Approved WMOCompleted
The aim of this phase IVI, randomized, open-label study is to compare the efficacy of cabazitaxel versus an AR targeted agent, in patients previously treated with docetaxel and likely to have primary resistance to AR targeted agents.